WO2000015256A2 - Emulsion immunostimulante - Google Patents
Emulsion immunostimulante Download PDFInfo
- Publication number
- WO2000015256A2 WO2000015256A2 PCT/FR1999/002177 FR9902177W WO0015256A2 WO 2000015256 A2 WO2000015256 A2 WO 2000015256A2 FR 9902177 W FR9902177 W FR 9902177W WO 0015256 A2 WO0015256 A2 WO 0015256A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- emulsion
- emulsion according
- molecule
- polynucleotide
- lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Definitions
- the invention relates to the field of vaccines and more particularly vaccine adjuvants.
- Vaccines whether prophylactic or therapeutic, are intended to stimulate the immune system of the human or animal body to which they are administered, the immune system response can be either a humoral type response (production of antibodies), either a cell type response, or a combination of the two types of responses.
- the immune system response can be either a humoral type response (production of antibodies), either a cell type response, or a combination of the two types of responses.
- vaccination has consisted in administering to an organism a non-pathogenic version of a microorganism so as to prepare the immune system to react effectively in the event that the organism is subsequently caused to encounter the same microorganism, in its pathogenic version.
- the antigen administered during vaccination can.
- oligonucleotides that may immunostimuiatrice activity
- these oligonucleotides can be administered as a vaccine adjuvant.
- This reference also mentions the possibility of associating with these oligonucleotides by ionic, covalent bond or by encapsulation, means for targeting the administration of the oligonucleotide.
- Such means can in particular consist of sterol, of lipid (for example a catiodic lipid, a virosome or a liposome) or of a binding agent specific to the target cell (for example a binder recognized by a receptor specific for the cell). target).
- the invention relates to an immu ⁇ ostimulant emulsion of the oil in water type, comprising at least one aqueous phase and one oily phase, characterized in that it also comprises at least one immunostimulating polynucleotide of which at least a part is covalently coupled to at least one lipid molecule.
- oil-in-water emulsion means a dispersion of oil droplets in an aqueous phase which may consist of a buffer such as the PBS buffer.
- the oily phase consists of a pharmaceutically acceptable oil, which can be a mineral, animal or vegetable oil.
- a metabolizable oil is used such as squalene, esters (in particular ethyl oleate, - j - isopropyl myristate), a vegetable oil (for example castor oil, sunflower oil, olive oil ...) or a modified vegetable oil (eg macrogol glycerides) .
- a satisfactory emulsion by mixing 500 mg of squalene with 10 ml of PBS buffer in a device such as an ULTRA-TURRAX TM, then by microfluidizing the dispersion obtained using a microfluidizer such as Microfluidics TM, which allows to obtain oily particles whose diameter is less than 200 nm.
- a surface-active agent in particular a surface-active agent whose HLB value (Hydrophilic / Lipophilic Balance) is between 6 and 14.
- a surfactant chosen from the list of the following products: sorbitan esters and poiysorbates, ethoxylated castor oil hydrogenated or not, ethoxylated stearic acid, oleic alcohol 10 EO, cetostearyl alcohol 20 EO, glycerol stearate, propylene glycol stearate, lecithins, sodium lauryl sulfate, sodium stearate, ethoxylated glycerol cocoate. 70E, ethoxylated glycerol esters, ethoxylated oleic acids, l 'mannitan oleate. Particularly good results have been obtained using TWEEN TM 80.
- the emulsion obtained is considered to be immunostimulatory if it is capable of causing or increasing the stimulation of the immune system, for example when it is administered together with a vaccine antigen.
- the emulsion is used as an immunoadjuvant.
- This immuno-adjuvant activity can be expressed in different ways:
- - modify the nature of the response of the immune system to the administration of the antigen (for example, inducing a cellular response when the administration of the antigen alone provoked only a humoral response), - induce or increase the production of cytokines, or certain cytokines in particular
- polynucleotide within the meaning of the present invention, is understood a single-stranded oligonucleotide having from 6 to 100 nuciéotides, preferably from 6 to 30 nuciéotides It can be oligonbonucleotide, or o godesoxy ⁇ bo-nucleotide preferably polynucleotides comprising basic sequences with reverse symmetry, as is the case in palindromic sequences (that is to say sequences of the ABCDEE'D'C'B'A 'type where A and A, B and B ', C and C, D and D' E and E 'are complementary bases in the sense of Watson and C ⁇ ck), and more particularly polynucleotides comprising at least one di ⁇ ucleotide sequence Cytosine, Guanme, in which Cytosine and Guanine are not methylated Any other polynucleotide known to be, by its very nature, immunostimulant, may be suitable for
- At least one lipid molecule is covalently coupled to the polynucleotide.
- This lipid molecule is preferably a cholesterol or cholesterol derivative molecule.
- the coupling can be carried out by covalent bonding at one or at each end of the polynucleotide, or again by inserting at least one lipid molecule next to each base.
- Antigens whose effect it is possible to potentiate thanks to the emulsion according to the present invention, can be of varied nature, it can in particular be proteins, glycoproteins, glycoconjugates, polysaccharides or polynucleotides comprising fractions of DNA likely to lead to the expression of molecules ules of interest, it can also be a mixture of different antigens. Particularly good results have been obtained with a composition comprising influenza antigens as they are present in the commercial vaccine VAXIGRIP TM
- An emulsion according to the invention can be obtained by proceeding in the following manner, first mixing, with stirring, the oil with the aqueous phase optionally consisting of a buffer solution in which a surfactant has been incorporated.
- the mixture obtained is homogenized. by means, for example, of a propeller stirrer, in order to lead to an emulsion of the type oil in water.
- the emulsion obtained is then treated using a microfluidizer in order to reduce the oil droplets to a diameter less than 200 nm
- this emulsion When this emulsion is intended to be used as an immunoadjuvant, it is mixed with stirring, to a composition comprising the antigen whose effect it is desired to potentiate.
- the mixing can advantageously be carried out in a volume ratio of 1. verify the unexpected effect and in particular the synergistic effect obtained on the stimulation of the immune system by the simultaneous use of a polynucleotide coupled to at least one lipid molecule, and its incorporation into an oil-in-water emulsion
- compositions comprising only the antigen or the mixture of antigens vis-à-vis which it is desired to test the immunostimulating effect of the emulsion according to the invention, - or a composition, comprising the antigen or antigens d interest to which has been added a solution comprising only polynucleotides coupled to at least one lipid molecule,
- compositions comprising the antigen or antigens of interest to which has been added an oil-in-water type emulsion, without polynucleotide, or with a polynucleotide lacking immunostimulatory activity with respect to the antigens administered,
- composition comprising the antigen or antigens of interest to which an emulsion according to the invention has been added
- the results obtained showed a significant synergistic effect of the elements constituting the emulsion according to the invention.
- the emulsion obtained according to the invention has increased stability compared to emulsions of the same nature, i.e. those consisting of an identical aqueous phase and an oily phase, but devoid of polynucleotides.
- Oligonucleotides are prepared using a synthesizer automaton provided by Applied Biosystems which implements the standard chemical method with phosphoramidite and which includes an oxidation step at each cycle. This oxidation step is carried out using an iodine / water / tetrahydrofuran / acetonitrile solution to obtain a phosphodiester bond and using a tetraethylthiuram / acetonitrile solution to obtain a phosphorothioate bond.
- a 3 Db (S) oligonucleotide is thus prepared, the sequence of which is reproduced under SEQ ID NO 1 and which comprises phosphorothioate bonds over its entire length.
- An MGC (S) oligonucleotide is also prepared, the sequence of which is reproduced in SEQ ID NO 2, which comprises both phosphodiester bonds and phosphorothioate bonds.
- the phosphorothiate bonds are located at each end; there are 2 phosphorothioate bonds in 3 'and 5 phosphorothioate bonds in 5'.
- This oligonucleotide does not have a palindromic sequence, and in particular no CG sequence.
- Oligonucleotides are prepared which are coupled to the ends of the cholesterol molecules.
- the synthesis of these 3 Db (S) -chol oligonucleotides and MGC (S) -chol is carried out in the same manner as in Example 1, with the exception of the Phosphoramidite reagent which is replaced by a specific reagent, Cholesterol-ON TM Phosphoramidite supplied by the company CLONTECH Lab. Inc, (USA), during the first and last synthesis cycle in order to obtain a cholesterol molecule inserted before each of the end nucleotides.
- the nucleotide sequences obtained are identical to those of the oligonucleotides described in the previous example.
- An immunostimulatory emulsion according to the invention is prepared by mixing 435 ⁇ l of the 2.3 g / l solution of 3Db (S) coupled to the cholesterol obtained in Example 2 (ie 1 mg of oligonucleotide), with 2 ml of the squalene / PBS emulsion obtained in Example 3, kept stirring.
- Another emulsion is prepared by mixing 263 ⁇ l of the 3.81 g / l solution of MGC (S) coupled with cholesterol obtained in Example 2 (ie 1 mg of oligonucleotide) with 2 ml of the squalene emulsion / PBS obtained in Example 3, kept stirring.
- Example 5
- Immunization doses of different natures are prepared by adding, with stirring, 2 ml of splitted vaccine against influenza NIB16 (monovalent A / Singapore H1 N1) containing 100 ⁇ g of hemagglutinin HA in PBS buffer to 2 ml of each of the following preparations •
- mice There are groups of 6 Balb / c female mice aged 6 to 8 weeks, each group corresponding to one of the preparations carried out in Example 6
- Each of the mice is immunized with 200 ⁇ l of the preparation corresponding to its group and therefore receives 5 ⁇ g of HA by immunization, each mouse being immunized 2 times 3 weeks apart, with the same preparation 2 weeks after the second injection, the response to specific anti-HA antibodies is measured, using an ELISA test, and the GMT for lgG1 as well as for lgG2a The results obtained are indicated below:
- results obtained confirm that the oligonucleotide 3Db (S) is well endowed with immunostimulatory properties because it is capable of inducing an increase in the antibody response compared to what is obtained during the administration of the antigens alone.
- results obtained with the oligonucleotide MGC (S) do not demonstrate immunostimulatory activity.
- the emulsion containing an immunostimulating polynucleotide such as the polynucleotide 3Db (S) leads to a production of antibodies clearly greater than that obtained with an emulsion containing the polynucleotide MGC (S) -chol; this effect is even more remarkable with regard to the production of IgG2a; which is indicative of an orientation of the immune response towards a TH1 type, orientation sometimes desired in certain vaccine targets.
- Vaccine compositions are prepared comprising the following elements:
- the doses are 50 ⁇ litres and include 50 micrograms of oligonucleotides.
- compositions are administered to mice at OJ and D28; 5 to 6 weeks after the booster injection, the spleens of the mice are removed in order to evaluate the amount of n ⁇ interferer produced.
- Immunization doses are prepared identical to those of Example 7, with the exception of the RSV antigens which are not in the presence of aluminum gel.
- the doses of 50 ⁇ litres are administered intramuscularly to groups of 6 mice.
- mice 4 weeks after immunization, the mice are bled and the anti-F protein antibody levels are determined by ELISA titration. The results obtained are summarized in the following table:
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU56278/99A AU749282B2 (en) | 1998-09-11 | 1999-09-13 | Immunostimulant emulsion |
US09/786,532 US6610308B1 (en) | 1998-09-11 | 1999-09-13 | Immunostimulant emulsion |
NZ510419A NZ510419A (en) | 1998-09-11 | 1999-09-13 | A vaccine adjuvant that is an oil-in-water immunoslimulant emulsion |
CA002342313A CA2342313A1 (fr) | 1998-09-11 | 1999-09-13 | Emulsion immunostimulante |
EP99942961A EP1121148A2 (fr) | 1998-09-11 | 1999-09-13 | Emulsion immunostimulante |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9811520A FR2783170B1 (fr) | 1998-09-11 | 1998-09-11 | Emulsion immunostimulante |
FR98/11520 | 1998-09-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000015256A2 true WO2000015256A2 (fr) | 2000-03-23 |
WO2000015256A3 WO2000015256A3 (fr) | 2000-07-13 |
Family
ID=9530468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/002177 WO2000015256A2 (fr) | 1998-09-11 | 1999-09-13 | Emulsion immunostimulante |
Country Status (7)
Country | Link |
---|---|
US (1) | US6610308B1 (fr) |
EP (1) | EP1121148A2 (fr) |
AU (1) | AU749282B2 (fr) |
CA (1) | CA2342313A1 (fr) |
FR (1) | FR2783170B1 (fr) |
NZ (1) | NZ510419A (fr) |
WO (1) | WO2000015256A2 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002028428A2 (fr) * | 2000-10-06 | 2002-04-11 | Aventis Pasteur | Composition vaccinale |
US7674777B2 (en) | 1994-07-15 | 2010-03-09 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US7998492B2 (en) | 2002-10-29 | 2011-08-16 | Coley Pharmaceutical Group, Inc. | Methods and products related to treatment and prevention of hepatitis C virus infection |
US8114419B2 (en) | 2002-07-03 | 2012-02-14 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US8202688B2 (en) | 1997-03-10 | 2012-06-19 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US8580268B2 (en) | 2006-09-27 | 2013-11-12 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
EP1434602B1 (fr) * | 2001-10-06 | 2014-12-17 | Merial Limited | CpG plus huile en eau émulsions adjuvants pour herpèsvirus bovin de type 1 glycoprotéine D tronquéeÜ |
US10837018B2 (en) | 2013-07-25 | 2020-11-17 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
NZ518999A (en) * | 1999-11-19 | 2002-12-20 | Csl Ltd | Vaccine compositions |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
SI1446162T1 (sl) | 2001-08-17 | 2009-04-30 | Coley Pharm Gmbh | Kombinacija zaporedja imunostimulatornih oligonukleotidov z izboljšano aktivnostjo |
US7569553B2 (en) | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
CA2536139A1 (fr) | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Conjugues lipophiles d'acides nucleiques |
AU2005326144A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
US10456463B2 (en) * | 2010-05-28 | 2019-10-29 | Zoetis Belgium S.A | Vaccines comprising cholesterol and CpG as sole adjuvant-carrier molecules |
CA2953216C (fr) | 2014-06-04 | 2020-12-22 | Exicure, Inc. | Liberation polyvalente de modulateurs immunitaires par des acides nucleiques spheriques liposomaux pour des applications prophylactiques ou therapeutiques |
CA2968531A1 (fr) | 2014-11-21 | 2016-05-26 | Northwestern University | Absorption cellulaire specifique a une sequence de conjugues nanoparticulaires d'acides nucleiques spheriques |
WO2018039629A2 (fr) | 2016-08-25 | 2018-03-01 | Northwestern University | Acides nucléiques sphériques micellaires obtenus à partir de matrices thermosensibles sans trace |
WO2018201090A1 (fr) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthèse d'acides nucléiques sphériques à l'aide de fractions lipophiles |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002555A1 (fr) * | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Oligonucleotides immunomodulateurs |
WO1998040100A1 (fr) * | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | UTILISATION D'ACIDES NUCLEIQUES CONTENANT UN DINUCLEOTIDE CpG NON METHYLE EN TANT QU'ADJUVANT |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866699A (en) * | 1994-07-18 | 1999-02-02 | Hybridon, Inc. | Oligonucleotides with anti-MDR-1 gene activity |
US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
-
1998
- 1998-09-11 FR FR9811520A patent/FR2783170B1/fr not_active Expired - Fee Related
-
1999
- 1999-09-13 EP EP99942961A patent/EP1121148A2/fr not_active Withdrawn
- 1999-09-13 US US09/786,532 patent/US6610308B1/en not_active Expired - Fee Related
- 1999-09-13 WO PCT/FR1999/002177 patent/WO2000015256A2/fr not_active Application Discontinuation
- 1999-09-13 AU AU56278/99A patent/AU749282B2/en not_active Ceased
- 1999-09-13 CA CA002342313A patent/CA2342313A1/fr not_active Abandoned
- 1999-09-13 NZ NZ510419A patent/NZ510419A/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002555A1 (fr) * | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Oligonucleotides immunomodulateurs |
WO1998040100A1 (fr) * | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | UTILISATION D'ACIDES NUCLEIQUES CONTENANT UN DINUCLEOTIDE CpG NON METHYLE EN TANT QU'ADJUVANT |
Non-Patent Citations (2)
Title |
---|
J.L. BITTLE ET AL., ED'S: "ADVANCES IN VETERINARY SCIENCE AND COMPARATIVE MEDICINE, VOL. 33, VACCINE BIOTECHNOLOGY." 1989 , ACADEMIC PRESS, INC. , SAN DIEGO, US XP002103839 * page 321, section D * * |
R.S. CHU ET AL.: "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity." JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 10, 17 novembre 1997 (1997-11-17), pages 1623-1631, XP002910130 NEW YORK, N.Y., US * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US8258106B2 (en) | 1994-07-15 | 2012-09-04 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7674777B2 (en) | 1994-07-15 | 2010-03-09 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7723500B2 (en) | 1994-07-15 | 2010-05-25 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US8129351B2 (en) | 1994-07-15 | 2012-03-06 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7879810B2 (en) | 1994-07-15 | 2011-02-01 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7888327B2 (en) | 1994-07-15 | 2011-02-15 | University Of Iowa Research Foundation | Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
US8202688B2 (en) | 1997-03-10 | 2012-06-19 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
US8173141B2 (en) | 1999-02-17 | 2012-05-08 | Csl Limited | Immunogenic complexes and methods relating thereto |
FR2814958A1 (fr) * | 2000-10-06 | 2002-04-12 | Aventis Pasteur | Composition vaccinale |
WO2002028428A3 (fr) * | 2000-10-06 | 2003-02-20 | Aventis Pasteur | Composition vaccinale |
WO2002028428A2 (fr) * | 2000-10-06 | 2002-04-11 | Aventis Pasteur | Composition vaccinale |
EP1434602B1 (fr) * | 2001-10-06 | 2014-12-17 | Merial Limited | CpG plus huile en eau émulsions adjuvants pour herpèsvirus bovin de type 1 glycoprotéine D tronquéeÜ |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US8114419B2 (en) | 2002-07-03 | 2012-02-14 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7998492B2 (en) | 2002-10-29 | 2011-08-16 | Coley Pharmaceutical Group, Inc. | Methods and products related to treatment and prevention of hepatitis C virus infection |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US8580268B2 (en) | 2006-09-27 | 2013-11-12 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US9382545B2 (en) | 2006-09-27 | 2016-07-05 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US10260071B2 (en) | 2006-09-27 | 2019-04-16 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US10837018B2 (en) | 2013-07-25 | 2020-11-17 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
Also Published As
Publication number | Publication date |
---|---|
FR2783170A1 (fr) | 2000-03-17 |
FR2783170B1 (fr) | 2004-07-16 |
US6610308B1 (en) | 2003-08-26 |
AU5627899A (en) | 2000-04-03 |
AU749282B2 (en) | 2002-06-20 |
WO2000015256A3 (fr) | 2000-07-13 |
CA2342313A1 (fr) | 2000-03-23 |
EP1121148A2 (fr) | 2001-08-08 |
NZ510419A (en) | 2003-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1121148A2 (fr) | Emulsion immunostimulante | |
EP1326636B1 (fr) | Composition vaccinale | |
US5994318A (en) | Cochleate delivery vehicles | |
JP4535211B2 (ja) | コクリエート送達ビヒクル | |
WO1996014831A1 (fr) | Adjuvant pour composition vaccinale | |
EP0918541B9 (fr) | Formulation de lipides immunostimulants | |
EP1750707A1 (fr) | Composition immunostimulante comprenant au moins un agoniste des recepteurs toll-like 7 ou du recepteur toll-like 8 et un agoniste du recepteur toll-like 4 | |
WO1999051269A1 (fr) | Vaccins adn adjuves | |
CA2246754C (fr) | Vecteurs d'apport de structures cochleaires | |
EP1696954B1 (fr) | Composition vaccinale adjuvantée par une alkylphosphatidylcholine | |
EP1024830B1 (fr) | Vecteurs d'antigenes sous forme de vesicules multilamellaires | |
CA2406949A1 (fr) | Utilisation de vecteurs particulaires dans l'immunomodulation | |
EP0748214B1 (fr) | Liposomes, et leur utilisation notamment pour l'obtention de compositions immunomodulatrices | |
AU753008B2 (en) | Cochleate delivery vehicles | |
FR2692148A1 (fr) | Composition adjuvante de l'immunité humorale et à médiation cellulaire n'induisant pas de réponse vis-à-vis de déterminants auto-antigéniques. | |
CN117897487A (en) | Application of artificially synthesized CpG-containing single-chain deoxyoligonucleotide in vaccine | |
WO1993025236A1 (fr) | Composition adjuvante de l'immunite humorale et a mediation cellulaire n'induisant pas de reponse vis-a-vis de determinants auto-antigeniques | |
WO2004103408A2 (fr) | Composition vaccinale comprenant du phosphate de fer a titre d’adjuvant vaccinal | |
FR2805163A1 (fr) | Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale | |
FR2808194A1 (fr) | Utilisation de particules hydrophiles portant ou non des ligands ioniques pour ameliorer les proprietes immunomodulatrices d'une substance autre qu'un antigene, et les compositions pharmaceutiques ainsi obtenues | |
WO1986007365A1 (fr) | Produits resultant de la conjugaison d'un support macromoleculaire, d'un haptene et d'un muramyl-peptide. | |
AU2006236007A1 (en) | Cochleate Delivery Vehicles | |
WO2004073596A2 (fr) | Composition vaccinale comprenant un antigene proteique du vih incorpore dans des vesicules lipidiques multilamellaires. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999942961 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 56278/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2342313 Country of ref document: CA Ref country code: CA Ref document number: 2342313 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 510419 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09786532 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999942961 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 56278/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999942961 Country of ref document: EP |